RTSL (Rapid Therapeutic Science Laboratories) Short-Term Debt: $3.30 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rapid Therapeutic Science Laboratories Short-Term Debt?

Rapid Therapeutic Science Laboratories RTSL Short-Term Debt is $3.30 Mil as of Jun. 2023.

Rapid Therapeutic Science Laboratories's Short-Term Debt for the quarter that ended in Jun. 2023 was $3.30 Mil.

Rapid Therapeutic Science Laboratories's quarterly Short-Term Debt declined from Dec. 2022 ($3.30 Mil) to Mar. 2023 ($3.27 Mil) but then increased from Mar. 2023 ($3.27 Mil) to Jun. 2023 ($3.30 Mil).

Rapid Therapeutic Science Laboratories's annual Short-Term Debt increased from Mar. 2020 ($0.91 Mil) to Dec. 2021 ($1.38 Mil) and increased from Dec. 2021 ($1.38 Mil) to Dec. 2022 ($3.30 Mil).

Rapid Therapeutic Science Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Rapid Therapeutic Science Laboratories Short-Term Debt Related Terms

Rapid Therapeutic Science Laboratories Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Rapid Therapeutic Science Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories Short-Term Debt Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.74 0.91 1.38 3.30

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 3.24 3.30 3.27 3.30
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $3.30 Mil mean?
Rapid Therapeutic Science Laboratories (RTSL) has a Short-Term Debt of $3.30 Mil as of Jun. 2023.
Is Rapid Therapeutic Science Laboratories' Short-Term Debt too high?
Rapid Therapeutic Science Laboratories' current Short-Term Debt is $3.30 Mil.
How does Rapid Therapeutic Science Laboratories' Short-Term Debt compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' Short-Term Debt of $3.30 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Diversified Financial Services company?
A good Short-Term Debt depends on the Diversified Financial Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Rapid Therapeutic Science Laboratories's current Short-Term Debt is $3.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current Short-Term Debt of $3.30 Mil. The current Short-Term Debt is $3.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current Short-Term Debt is $3.30 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Therapeutic Science Laboratories Business Description

Address 558 County Road 472, De Leon, TX, USA, 76444
Rapid Therapeutic Science Laboratories Inc currently has no operations and operates as a blank check company.